Evaluation of primary prophylaxis with granulocyte colony-stimulating factor for epithelial ovarian cancer
1Department of Obstetrics and Gynecology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto (Japan)
DOI: 10.12892/ejgo23932014 Vol.35,Issue 1,January 2014 pp.48-51
Published: 10 January 2014
Purpose: Primary prophylaxis with G-CSF has been used to minimize myelosuppression caused by anticancer agents and to avoid severe neutropenia. The authors retrospectively examined the value of primary prophylaxis using granulocyte colony-stimulating factor (G-CSF) for epithelial ovarian cancer. Materials and Methods: From 2001 to 2010, 105 patients with ovarian cancer receiving chemotherapy in the present hospital were divided into two groups: one received primary prophylaxis with G-CSF and the other did not receive it in compliance with the guidelines for G- CSF usage. The incidence of febrile neutropenia (FN), degree of neutropenia, frequency of G-CSF administration, number of days of hospitalization, progression-free survival (PFS), and overall survival (OS) were evaluated. Results: Neutrophils decreased almost equally and the length of hospitalization was not significantly lower between the groups. Five-year PFS or OS showed no significant difference either. Conclusions: Primary prophylaxis with G-CSF in chemotherapy for epithelial ovarian cancer could be of low significance.
Epithelial ovarian cancer; Primary prophylaxis; Granulocyte colony-stimulating factor; Febrile neutropenia.
K. Matsui,T. Mori,M. Sawada,H. Kuroboshi,H. Tatsumi,T. Yoshioka,M. Akiyama,T. Yamamoto,K. Iwasaku,J. Kitawaki. Evaluation of primary prophylaxis with granulocyte colony-stimulating factor for epithelial ovarian cancer. European Journal of Gynaecological Oncology. 2014. 35(1);48-51.
 Bodey G.P., Buckley M., Monica B., Sathe Y.S.: “Quantitative Relationships Between Circulating Leukocytes and Infection Patients with Acute Leukemia”. Ann. Intern. Med., 1966, 64, 328.
 Official Journal of the Japan Society of Clinical Oncology: “G- CSF guideline for an appropriate usage”. Int. J. Clin. Oncol., 2001, 6, 1.
 Thomas J.S., James K., Lyman G.H., Howard O., James O.A., Lodovico B. et al.: “2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline”. J. Clin. Oncol., 2006, 24, 3187.
 Masaoka T.: “Conclusions and recommendations: Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan”. Int. J. Hematol., 1998, 68, S39.
 Vital Statistics Japan (Ministry of Health. Labor and Welfare): Center for Cancer Control and Information Services, National Cancer Center, Japan, 2006. Updated January 27, 2011.
 Heintz A.P., Odicino F., Maisonneuve P.: “Carcinoma of the Ovary”. Int. J. Gynecol. Obstets., 2003, 83, 135.
 Crawford J., Howard O., Ronald S., David J., Gary L., Imad T. et al.: “Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer”. N. Engl. J. Med., 1991, 523, 164.
 Ruth P., Howard G., John A.R., David P.D., Roger J., Peter M.W. et al.: “Granulocyte Colony-Stimulating Factor to Prevent Dose-Limiting Neutropenia in Non-Hodgkin’s Lymphoma”. Blood, 1992, 80, 1430.
 Kuderer N.M., Dale D.C., Crawford J., Lyman G.H.: “Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy”. J. Clin. Oncol., 2007, 25, 3158.
 Jean K., Marianne P., Edward B.R., Michael B., Linda E., Ronald F. et al.: “The Multinational Association of Supportive Care in Cancer Risk Index.A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients”. J. Clin. Oncol., 2000, 18, 3038.
 Jean K., Marianne P., Asoasia G., Frederique M., Barbara P., Laurent D. et al.: “Outpatient Oral Antibiotics for Febrile Neutropenic Cancer Patients Using a Predictive for Complications”. J. Clin. Oncol., 2006, 24, 4129.
 Tamura K.: “Initial empirical antimicrobial therapy: Duration and Subsequent Modefications”. Clin. Infect. Dis., 2004, 39, 59.
 Walter T.H., Donald A., Gerald P.B., Eric J.B., Arthur E.B., Thierry C. et al.: “2002 Guidelines for the Use Antimicrobial Agents in Neutropenic Patients with Cancer”. Clin. Infect. Dis., 2002, 34, 730.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.